•
Jul 03, 2021

Waters Q2 2021 Earnings Report

Waters' second quarter performance in 2021 was strong, with sales growth driven by pharmaceutical and industrial end markets and increased customer demand across key regions.

Key Takeaways

Waters Corporation reported a 31% increase in sales to $682 million in Q2 2021 compared to $520 million in Q2 2020. GAAP EPS increased to $2.69 from $1.98, while non-GAAP EPS increased to $2.60 from $2.10. The company saw strong growth in the pharmaceutical and industrial markets, with sales increasing across all regions.

Sales of $682 million grew 31% as reported and 27% in constant currency.

GAAP EPS of $2.69; non-GAAP EPS of $2.60, a 24% increase from prior year.

Broad-based commercial momentum in pharmaceutical and industrial end markets.

Continued strength in core and new product instrument and chemistry sales.

Total Revenue
$682M
Previous year: $520M
+31.1%
EPS
$2.6
Previous year: $2.1
+23.8%
Pharma Market Sales
416,705,000%
Previous year: -11%
-3788227372.7%
Industrial Market Sales
202,579,000%
Previous year: -14%
-1446992957.1%
Academic & Gov Sales
62,363,000%
Previous year: -22%
-283468281.8%
Gross Profit
$401M
Previous year: $307M
+30.8%
Cash and Equivalents
$460K
Previous year: $339M
-99.9%
Free Cash Flow
$155M
Previous year: $175M
-11.7%
Total Assets
$3.1B
Previous year: $2.65B
+17.2%

Waters

Waters

Waters Revenue by Segment

Waters Revenue by Geographic Location

Forward Guidance

The Company expects third quarter 2021 constant-currency sales growth in the range of 7% to 9%. Currency translation is expected to increase third quarter sales growth by approximately one percentage point. The Company also expects third quarter 2021 non-GAAP EPS in the range of $2.25 to $2.35.

Revenue & Expenses

Visualization of income flow from segment revenue to net income